Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.
The move follows Simon Sturge’s resignation as non-executive director of the biotechnology company as he seeks to focus on his other business commitments.
Dr Collinson has held senior management roles in public and private life science companies across Europe and the US, including at GlaxoWellcome, now GlaxoSmithKline, Baxter International and Cabrellis Pharmaceuticals, now part of Celgene.
He is a partner of US-based VC firm Forward Ventures and currently also serves as chairman and chief executive officer of Tioga Pharmaceuticals and director for both Arcturus Therapeutics and Essentialis.
Chief executive officer of Silence Therapeutics Ali Mortazavi said: “We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe.”